Trehalose

ApprovedSmall molecule

SSeelos Therapeutics, Inc.

Trehalose is one of 151 small molecule programs targeting Muscular Dystrophy. It is currently in Approved.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muscular DystrophyActive, not recruiting

Parkinson DiseaseActive, not recruiting

CataractActive, not recruiting

Type 2 DiabetesActive, not recruiting

NeuropathyActive, not recruiting

Muscular DystrophyPhase 2

Active, not recruiting

Parkinson DiseaseApproved

Active, not recruiting

CataractApproved

Active, not recruiting

Type 2 DiabetesPhase 1

Active, not recruiting

NeuropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Trehalose

SSeelos Therapeutics, Inc.

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 9

Forxiga

AstraZeneca

Preclinical

3 10

Lovaza

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Type 2 Diabetes

NCT05593549

Clinical

Trials by Indication[1]

Inflammation1 trial

Inflammation Reduction by TREhalose AdminisTration

Unknown status·MMashhad University of Medical Sciences·Phase 2·NCT03700424·15 enrolled

Neuropathy1 trial

Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE)

Unknown status·MMashhad University of Medical Sciences·Phase 1·NCT04663854·20 enrolled

Cataract1 trial

The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers

Unknown status·UUnknown Sponsor·Phase 4·NCT05990712·68 enrolled

Muscular Dystrophy1 trial

Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose

Withdrawn·BBioblast Pharma Ltd.·Phase 2·NCT04226924

ESS1 trial

Intermediate-Sized Expanded Access Study

No longer available·SSeelos Therapeutics, Inc.··NCT05597436

3 more indications

Bipolar Depression1 trial

Trehalose as add-on Therapy in Bipolar Depression

Completed·CConsorcio Centro de Investigación Biomédica en Red (CIBER)·Phase 3·NCT02800161·60 enrolled

Parkinson disease1 trial

Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease

Unknown status·NNeuromed IRCCS·Phase 4·NCT05355064·20 enrolled

Type 2 Diabetes1 trial

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

Recruiting·MMedical College of Wisconsin·Phase 1·NCT05593549·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Trehalose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trehalose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trehalose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seelos Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSeelos Therapeutics, Inc.

Trehalose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Inflammation1 trial

Neuropathy1 trial

Cataract1 trial

Muscular Dystrophy1 trial

ESS1 trial

Bipolar Depression1 trial

Parkinson disease1 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News